Compare Samsara Inc (IOT) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Samsara Inc vs Repligen Corporation Common Stock — how do they compare? Samsara Inc trades at $40.5 (market cap $24.17B), while Repligen Corporation Common Stock trades at $178.86 (market cap $11.14B). The key difference: Samsara Inc is far larger — about 2.2× Repligen Corporation Common Stock's market cap, and Samsara Inc is more actively traded (3,228,585 versus 1,259,263). Which is the better fit depends on your goals — on Pluang, investors hold Samsara Inc for 19 Days and Repligen Corporation Common Stock for 0 Days on average.
| IOT | RGEN | |
|---|---|---|
Market Cap | $24.17B | $11.14B |
Volume | 3,228,585 | 1,259,263 |
Sector | Technology | Health |
52-Week High | $45.22 | $194.57 |
52-Week Low | $24.25 | $102.87 |
Typical Hold Time | 19 Days | 0 Days |
Enterprise Value | $23.41B | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Samsara Inc. (IOT) trades at $41.27, down 0.84% today, with a bullish technical signal from moving averages and a consensus analyst price target of $51.15. The company reported strong Q2 2026 earnings, beating EPS estimates with $0.20 versus $0.16 expected, and revenue growth of 30% year-over-year. Recent news highlights partnerships and product launches, including the Samsara MCP for AI integration and a rewards program for drivers.
The outlook is positive due to robust revenue growth, expanding large-customer base, and analyst optimism, but risks include high valuation multiples (P/E of 275.13) and cash flow pressures. Investment opportunity lies in continued execution and market share gains, while investors should monitor margin sustainability and competitive dynamics.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Samsara Inc
Samsara provides a connected operations cloud that uses IoT data to help businesses improve efficiency and safety. Its platform offers real-time visibility for fleet management, equipment monitoring, and industrial sites.
Read more on IOT →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
